Great news for immunotherapy of liver cancer! Mercadon Keytruda has been approved by the FDA to treat hepatocellular carcinoma

The U.S. Food and Drug Administration (FDA) has approved a new adaptation of the PD-1 oncology immunotherapy Keytruda (Chinese commodity name: Corida, common name: Pabli pearl monoantigen) for patients with hepatocellular carcinoma (HCC) who have previously been treated with the targeted drug sorafenib( sorafenib). It also marks Keytruda's 14th adaptation to FDA regulation in the United States, and this approval is based on accelerated approval based on tumor mitigation rate and mitigation persistence data, and further approval will depend on the validation and description of clinical benefits in corroroical clinical studies.
It's worth noting that at the end of last month, the FDA also approved Keytruda combined chemotherapy (capablatin-yew alcohol or albumin-binding yew alcohol (nab-paclitaxel)) for first-line treatment in patients with metastasis squamous non-small cell lung cancer (squamous NSCLC), regardless of the state of expression of tumor PD-L1. This approval makes Keytruda the first PD-1 tumor immunotherapy to treat squamous NSCLC regardless of tumor PD-L1 expression status.
approval of Keytruda HCC adaptations is based on data from the KEYNOTE-224 study. The study, a single open-label study, assessed the efficacy and safety of Keytruda's treatment in 104 patients with HCC who developed the disease during or after treatment with sorafenib.
, the total remission rate (ORR) for Keytruda treatment was 17% (95% CI:11-26), with a total remission rate of 1% and a partial remission rate of 16%. In patients with remission (n-18), 89% of patients had a duration of remission (DOR) of 6 months or more, and 56% of patients had DOR of 12 months or more.
Dr. Andrew X. Zhu, lead researcher on the study and director of liver cancer research at Massachusetts General Hospital and a professor of medicine at Harvard Medical School, said HCC is the most common type of cancer in adults, and while some progress has been made in recent years, treatment options for advanced relapse disease remain limited. This Keytruda approval is important and will provide a new treatment option for HCC patient groups that have previously received sorafenib treatment.Dr. Cot Ebbinghaus, Vice President of Clinical Research at
Mercer East Research Laboratory, said keytruda's approval of late-stage HCC adaptation marks the second FDA approval this year for the company's oncology pipeline treatment HCC, underscoring our strong commitment to providing new treatment options for historically challenging cancers. We look forward to continuing HCC research to help more patients affected by this type of cancer.
, liver cancer is the second leading cause of cancer deaths, with 780,000 new cases and about 750,000 deaths each year. Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancer cases, the early stage of HCC can be treated by a variety of means, including surgical excision, radio frequency ablation, waterless ethanol injection, chemotherapy embolism treatment and so on, but the treatment options of non-excisive HCC are very limited, the prognosis is very poor, resulting in a significant unsolved medical needs in this field. Clinically, Bayer's targeting of the cancer drug Nexavar (common name: sorafenib, sorafini) is a standard molecular targeting drug for the first-line treatment of non-excisible HCC.
there are large regional differences in liver cancer, with the majority of cases occurring in Asia, first in China and then in Africa. HCC is associated with chronic liver disease, especially cirrhosis. The main causes of cirrhosis include hepatitis B virus and hepatitis C virus infection. However, according to a recent survey, non-hepatitis B/C-hepatocellular carcinoma is on the rise. (Bio Valley)